1. The therapeutic role of ivabradine in heart failure
- Author
-
Charles Badu-Boateng, Robert Jennings, and Daniel Hammersley
- Subjects
medicine.medical_specialty ,Ejection fraction ,business.industry ,Sinoatrial node ,Medicine (miscellaneous) ,Review ,030204 cardiovascular system & hematology ,medicine.disease ,Review article ,Clinical trial ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Pharmacotherapy ,Internal medicine ,Heart failure ,Heart rate ,Cardiology ,Medicine ,030212 general & internal medicine ,business ,Ivabradine ,medicine.drug - Abstract
Heart failure represents a major global cause of morbidity and mortality. Ivabradine is a selective funny current (If) inhibitor, which acts on the sinoatrial node, resulting in a reduction in heart rate. Ivabradine is currently licensed for use in patients with symptomatic heart failure with reduced ejection fraction and a heart rate persistently at least 70 beats per minute in spite of otherwise optimal prognostic heart failure pharmacotherapy. In this review article, we examine the mechanism of action of ivabradine, evaluate the clinical trials underpinning its application in heart failure and discuss its current recommended clinical use in this capacity.
- Published
- 2018